Late onset Wilson's disease: Therapeutic implications
Identifieur interne : 003584 ( Istex/Corpus ); précédent : 003583; suivant : 003585Late onset Wilson's disease: Therapeutic implications
Auteurs : Anna Członkowska ; Maria Rodo ; Gra Yna GromadzkaSource :
- Movement Disorders [ 0885-3185 ] ; 2008-04-30.
English descriptors
- KwdEn :
Abstract
The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are ATP7B mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.21985
Links to Exploration step
ISTEX:5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Late onset Wilson's disease: Therapeutic implications</title><author><name sortKey="Czlonkowska, Anna" sort="Czlonkowska, Anna" uniqKey="Czlonkowska A" first="Anna" last="Członkowska">Anna Członkowska</name><affiliation><mods:affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Rodo, Maria" sort="Rodo, Maria" uniqKey="Rodo M" first="Maria" last="Rodo">Maria Rodo</name><affiliation><mods:affiliation>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Gromadzka, Gra Yna" sort="Gromadzka, Gra Yna" uniqKey="Gromadzka G" first="Gra Yna" last="Gromadzka">Gra Yna Gromadzka</name><affiliation><mods:affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21985</idno><idno type="url">https://api.istex.fr/document/5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003584</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Late onset Wilson's disease: Therapeutic implications</title><author><name sortKey="Czlonkowska, Anna" sort="Czlonkowska, Anna" uniqKey="Czlonkowska A" first="Anna" last="Członkowska">Anna Członkowska</name><affiliation><mods:affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Rodo, Maria" sort="Rodo, Maria" uniqKey="Rodo M" first="Maria" last="Rodo">Maria Rodo</name><affiliation><mods:affiliation>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Gromadzka, Gra Yna" sort="Gromadzka, Gra Yna" uniqKey="Gromadzka G" first="Gra Yna" last="Gromadzka">Gra Yna Gromadzka</name><affiliation><mods:affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30">2008-04-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="896">896</biblScope><biblScope unit="page" to="898">898</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6</idno><idno type="DOI">10.1002/mds.21985</idno><idno type="ArticleID">MDS21985</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Wilson's disease</term><term>genotype</term><term>late onset</term><term>phenotype</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are ATP7B mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anna Członkowska MD, PhD</name><affiliations><json:string>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</json:string><json:string>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Maria Rodo PhD</name><affiliations><json:string>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Grażyna Gromadzka PhD</name><affiliations><json:string>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</json:string><json:string>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Wilson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>late onset</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genotype</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>phenotype</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are ATP7B mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society</abstract><qualityIndicators><score>3.081</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>689</abstractCharCount><pdfWordCount>1773</pdfWordCount><pdfCharCount>11658</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>109</abstractWordCount></qualityIndicators><title>Late onset Wilson's disease: Therapeutic implications</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>3</total><last>898</last><first>896</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21985</json:string></doi><id>5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Late onset Wilson's disease: Therapeutic implications</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Late onset Wilson's disease: Therapeutic implications</title><author><persName><forename type="first">Anna</forename><surname>Członkowska</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation><affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</affiliation></author><author><persName><forename type="first">Maria</forename><surname>Rodo</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation></author><author><persName><forename type="first">Grażyna</forename><surname>Gromadzka</surname><roleName type="degree">PhD</roleName></persName><note type="correspondence"><p>Correspondence: Second Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02‐957 Warsaw, Poland</p></note><affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation><affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="896">896</biblScope><biblScope unit="page" to="898">898</biblScope></imprint></monogr><idno type="istex">5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6</idno><idno type="DOI">10.1002/mds.21985</idno><idno type="ArticleID">MDS21985</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are ATP7B mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Wilson's disease</term></item><item><term>late onset</term></item><item><term>genotype</term></item><item><term>phenotype</term></item><item><term>treatment</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-08-03">Received</change><change when="2008-01-21">Registration</change><change when="2008-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v23:6</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2008-04-30">30 April 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21985</doi><idGroup><id type="unit" value="MDS21985"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-08-03"></event><event type="manuscriptRevised" date="2008-01-16"></event><event type="manuscriptAccepted" date="2008-01-21"></event><event type="firstOnline" date="2008-02-29"></event><event type="publishedOnlineFinalForm" date="2008-04-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-02-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">896</numbering><numbering type="pageLast">898</numbering></numberingGroup><correspondenceTo>Second Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02‐957 Warsaw, Poland</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21985.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="2210"></count></countGroup><titleGroup><title type="main" xml:lang="en">Late onset Wilson's disease: Therapeutic implications</title><title type="short" xml:lang="en">Late Presymptomatic Wilson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Anna</givenNames><familyName>Członkowska</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Maria</givenNames><familyName>Rodo</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Grażyna</givenNames><familyName>Gromadzka</familyName><degrees>PhD</degrees></personName><contactDetails><email>gromadz@ipin.edu.pl</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="PL" type="organization"><unparsedAffiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="PL" type="organization"><unparsedAffiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="PL" type="organization"><unparsedAffiliation>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Wilson's disease</keyword><keyword xml:id="kwd2">late onset</keyword><keyword xml:id="kwd3">genotype</keyword><keyword xml:id="kwd4">phenotype</keyword><keyword xml:id="kwd5">treatment</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are <i>ATP7B</i> mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Late onset Wilson's disease: Therapeutic implications</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Late Presymptomatic Wilson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Late onset Wilson's disease: Therapeutic implications</title></titleInfo><name type="personal"><namePart type="given">Anna</namePart><namePart type="family">Członkowska</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation><affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria</namePart><namePart type="family">Rodo</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Grażyna</namePart><namePart type="family">Gromadzka</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</affiliation><affiliation>Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland</affiliation><description>Correspondence: Second Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02‐957 Warsaw, Poland</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-04-30</dateIssued><dateCaptured encoding="w3cdtf">2007-08-03</dateCaptured><dateValid encoding="w3cdtf">2008-01-21</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">17</extent><extent unit="words">2210</extent></physicalDescription><abstract lang="en">The clinical symptoms of Wilson's disease (WD) usually develop between 3 and 40 years of age and include signs of liver and/or neurologic and psychiatric disease. We report on an 84‐year‐old woman with WD. Despite the absence of treatment, the only symptom she presented with, until the age of 74 years, was Kayser‐Fleisher rings. At the age of 74, she developed slightly abnormal liver function. This case raises the following issues: (a) Should WD be considered in all patients of all ages who manifest signs related to the disease? (b) Are ATP7B mutations fully penetrant? (c) Should all patients diagnosed presymptomatically receive anticopper therapy? © 2008 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Wilson's disease</topic><topic>late onset</topic><topic>genotype</topic><topic>phenotype</topic><topic>treatment</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>896</start><end>898</end><total>3</total></extent></part></relatedItem><identifier type="istex">5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6</identifier><identifier type="DOI">10.1002/mds.21985</identifier><identifier type="ArticleID">MDS21985</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003584 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003584 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5D10FB7B2FAB7B108F3BF3066A444F15A1A7EBC6
|texte= Late onset Wilson's disease: Therapeutic implications
}}
| This area was generated with Dilib version V0.6.23. |  |